Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.